These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 23275304

  • 1. Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone.
    Halevy O, Genin O, Barzilai-Tutsch H, Pima Y, Levi O, Moshe I, Pines M.
    Histol Histopathol; 2013 Feb; 28(2):211-26. PubMed ID: 23275304
    [Abstract] [Full Text] [Related]

  • 2. Early pathological signs in young dysf-/- mice are improved by halofuginone.
    Barzilai-Tutsch H, Genin O, Pines M, Halevy O.
    Neuromuscul Disord; 2020 Jun; 30(6):472-482. PubMed ID: 32451154
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Halofuginone promotes satellite cell activation and survival in muscular dystrophies.
    Barzilai-Tutsch H, Bodanovsky A, Maimon H, Pines M, Halevy O.
    Biochim Biophys Acta; 2016 Jan; 1862(1):1-11. PubMed ID: 26454207
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.
    Turgeman T, Hagai Y, Huebner K, Jassal DS, Anderson JE, Genin O, Nagler A, Halevy O, Pines M.
    Neuromuscul Disord; 2008 Nov; 18(11):857-68. PubMed ID: 18672370
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hydroxy group requirement for halofuginone-dependent inhibition of muscle fibrosis and improvement of histopathology in the mdx mouse model for Duchenne muscular dystrophy.
    Wellner G, Mordechay S, Evans P, Genin O, Pines M, Halevy O.
    Histol Histopathol; 2019 Jul; 34(7):791-801. PubMed ID: 30628720
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion.
    Roffe S, Hagai Y, Pines M, Halevy O.
    Exp Cell Res; 2010 Apr 01; 316(6):1061-9. PubMed ID: 20060825
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lipid accumulation in dysferlin-deficient muscles.
    Grounds MD, Terrill JR, Radley-Crabb HG, Robertson T, Papadimitriou J, Spuler S, Shavlakadze T.
    Am J Pathol; 2014 Jun 01; 184(6):1668-76. PubMed ID: 24685690
    [Abstract] [Full Text] [Related]

  • 16. Differential Effects of Halofuginone Enantiomers on Muscle Fibrosis and Histopathology in Duchenne Muscular Dystrophy.
    Mordechay S, Smullen S, Evans P, Genin O, Pines M, Halevy O.
    Int J Mol Sci; 2021 Jun 30; 22(13):. PubMed ID: 34209117
    [Abstract] [Full Text] [Related]

  • 17. Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy.
    Lee YS, Lehar A, Sebald S, Liu M, Swaggart KA, Talbot CC, Pytel P, Barton ER, McNally EM, Lee SJ.
    Hum Mol Genet; 2015 Oct 15; 24(20):5711-9. PubMed ID: 26206886
    [Abstract] [Full Text] [Related]

  • 18. Dysferlinopathy Promotes an Intramuscle Expansion of Macrophages with a Cyto-Destructive Phenotype.
    Baek JH, Many GM, Evesson FJ, Kelley VR.
    Am J Pathol; 2017 Jun 15; 187(6):1245-1257. PubMed ID: 28412297
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.